Asian Penny Stocks To Watch In May 2025

In This Article:

Amidst easing trade tensions and positive earnings reports, Asian markets are navigating a complex economic landscape marked by cautious optimism. In such a setting, penny stocks—often representing smaller or newer companies—offer intriguing growth opportunities at lower price points. While the term "penny stock" may seem outdated, these investments can still hold significant potential when backed by strong financial health and solid fundamentals.

Top 10 Penny Stocks In Asia

Name

Share Price

Market Cap

Financial Health Rating

Advice IT Infinite (SET:ADVICE)

THB4.84

THB3B

★★★★★★

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.41

SGD166.17M

★★★★★☆

YKGI (Catalist:YK9)

SGD0.10

SGD42.5M

★★★★★★

Beng Kuang Marine (SGX:BEZ)

SGD0.189

SGD37.65M

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.25

SGD8.86B

★★★★★☆

Ever Sunshine Services Group (SEHK:1995)

HK$1.93

HK$3.34B

★★★★★☆

Bosideng International Holdings (SEHK:3998)

HK$4.06

HK$46.48B

★★★★★★

Lever Style (SEHK:1346)

HK$1.06

HK$668.81M

★★★★★★

Goodbaby International Holdings (SEHK:1086)

HK$1.15

HK$1.92B

★★★★★★

TK Group (Holdings) (SEHK:2283)

HK$1.95

HK$1.62B

★★★★★★

Click here to see the full list of 1,170 stocks from our Asian Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

AIM Vaccine

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AIM Vaccine Co., Ltd. focuses on the research, development, manufacturing, and commercialization of vaccines for human use in China and has a market cap of approximately HK$4.29 billion.

Operations: The company's revenue primarily comes from the sale of vaccines and research and development services, totaling CN¥1.29 billion.

Market Cap: HK$4.29B

AIM Vaccine Co., Ltd. is positioned as a promising entity in the Asian penny stock landscape, driven by its focus on vaccine innovation and development. Despite being unprofitable with increasing losses over five years, AIM has shown resilience through its strategic advancements in mRNA technology. Recent approvals for clinical trials of its mRNA shingles and RSV vaccines by the U.S. FDA highlight its potential for international market penetration. The company's serum-free rabies vaccine marks a significant technological breakthrough, potentially enhancing safety and reducing adverse reactions compared to traditional vaccines, which may bolster future revenue growth prospects amidst high volatility in share price.

SEHK:6660 Revenue & Expenses Breakdown as at May 2025
SEHK:6660 Revenue & Expenses Breakdown as at May 2025

Youzan Technology

Simply Wall St Financial Health Rating: ★★★★★☆